The SENSCIS® study, co-led by Cleveland Clinic’s Kristin Highland, MD, explores the use of nintedanib in patients with scleroderma-associated interstitial lung disease.
Approved vasodilation therapies generally don’t improve function in patients with pulmonary hypertension associated with connective tissue disease. The Catalyst study explores the use of bardoxolone in these patients.
The TRAIL-1 study explores the use of pirfenidone, an antifibrotic agent approved for idiopathic pulmonary fibrosis, in patients with rheumatoid arthritis-associated interstitial lung disease.
Cleveland Clinic is part of the largest scleroderma trial ever undertaken to evaluate the efficacy and safety of oral nintedanib treatment in systemic sclerosis associated interstitial lung disease.